Gwenn Hansen Sells 3,437 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 3,437 shares of the firm’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $83,519.10. Following the transaction, the insider now directly owns 50,670 shares of the company’s stock, valued at $1,231,281. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Nurix Therapeutics Price Performance

NASDAQ NRIX traded down $1.13 during trading hours on Wednesday, hitting $24.07. The company’s stock had a trading volume of 761,824 shares, compared to its average volume of 885,869. The company’s 50 day simple moving average is $24.18 and its two-hundred day simple moving average is $20.14. The company has a market cap of $1.71 billion, a P/E ratio of -8.66 and a beta of 2.22. Nurix Therapeutics, Inc. has a 12 month low of $4.96 and a 12 month high of $27.60.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.67). The business had revenue of $12.59 million during the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. As a group, research analysts predict that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Nurix Therapeutics

A number of large investors have recently made changes to their positions in NRIX. Amalgamated Bank lifted its position in shares of Nurix Therapeutics by 30.6% during the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after buying an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Nurix Therapeutics by 31.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after buying an additional 559 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of Nurix Therapeutics by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock valued at $176,000 after buying an additional 998 shares in the last quarter. ClariVest Asset Management LLC lifted its position in shares of Nurix Therapeutics by 2.9% during the 2nd quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock valued at $1,318,000 after buying an additional 1,766 shares in the last quarter. Finally, Public Employees Retirement System of Ohio lifted its position in shares of Nurix Therapeutics by 3.7% during the 1st quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company’s stock valued at $747,000 after buying an additional 1,820 shares in the last quarter.

Analyst Ratings Changes

NRIX has been the subject of several recent research reports. Royal Bank of Canada lowered their price objective on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Barclays raised their price objective on Nurix Therapeutics from $20.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, July 15th. HC Wainwright lifted their price target on Nurix Therapeutics from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Truist Financial started coverage on Nurix Therapeutics in a research report on Wednesday, July 31st. They issued a “buy” rating and a $36.00 price target for the company. Finally, UBS Group started coverage on Nurix Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $35.00 price target for the company. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.40.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.